Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys.
Chronic treatment with the indirect dopamine agonist d-amphetamine can reduce cocaine use in clinical trials and, in preclinical studies in laboratory animals, attenuates daily cocaine self-administration. The present study extended previous results to conditions designed to reflect a more clinically relevant experience of cocaine exposure and d-amphetamine treatment. Each morning, monkeys pressed a lever to receive food pellets under a 50-response fixed-ratio schedule of reinforcement. After determining a dose-response curve for cocaine (0.003-0.56 mg/kg per injection, i.v.) under a progressive-ratio (PR) schedule of reinforcement in the evening, cocaine self-administration sessions were suspended and d-amphetamine (0.01-0.056 mg/kg/h, i.v.) was administered continuously for at least 24 days, except during cocaine self-administration sessions, which were conducted using the PR schedule once every 8 days. When a persistent decrease in self-administration was observed, the cocaine dose-effect curve was redetermined. Cocaine- and food-maintained responding were also examined after discontinuation of d-amphetamine. Although individual differences in sensitivity were observed, d-amphetamine produced selective, qualitatively similar decreases in the reinforcing strength of cocaine in all monkeys that persisted at least 4 weeks. Moreover, cocaine dose-effect curves were shifted downward and/or to the right. For 2 weeks following discontinuation of d-amphetamine treatment, the reinforcing strength of cocaine varied within and across individuals, however, on the whole no increased sensitivity was apparent. These data provide further support for the use of agonist medications for cocaine abuse, and extend the conditions under which such treatment is successful to those that incorporate clinically relevant patterns of cocaine use and drug treatment.
Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1083, USA.
Paul W
PW
Czoty
Robert W
RW
Gould
Jennifer L
JL
Martelle
Michael A
MA
Nader
D000818:Animals; D003042:Cocaine / Q000819:agonists*; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003913:Dextroamphetamine / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D018765:Dopamine Uptake Inhibitors / Q000819:agonists; D004334:Drug Administration Schedule; D008253:Macaca mulatta; D008297:Male; D012054:Reinforcement, Psychology; D012201:Reward; D012646:Self Administration; D013997:Time Factors
D018765:Dopamine Uptake Inhibitors; D003042:Cocaine; D003913:Dextroamphetamine